Meeting
2024 ASCO Genitourinary Cancers Symposium
Somatostatin receptor 1 (SSTR1) expression as a potential predictive biomarker for response to androgen receptor signaling inhibitor (ARSI) therapy in metastatic castration-resistant prostate cancer (mCRPC).
Authors
Xiaolin Zhu
University of California, San Francisco, San Francisco, CA
Xiaolin Zhu , Daniel J Vis , Martin Sjöström , Raunak Shrestha , Jeroen Kneppers , Tessa Severson , Yanyun Zhu , Haolong Li , Tatyanah Farsh , Meng Zhang , Arian Lundberg , Thaidy Moreno Rodriguez , Adam Foye , Andre M. Bergman , Wilbert Zwart , David Alan Quigley , Rahul Raj Aggarwal , Eric J. Small , Michiel Simon Van Der Heijden , Felix Y Feng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 180)
DOI
10.1200/JCO.2024.42.4_suppl.180
Abstract #
180
Poster Bd #
H9
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
First Author: Evan Y. Yu
Poster
2024 ASCO Genitourinary Cancers Symposium
Association of a prostate cancer gastrointestinal transcriptional phenotype as found in clinical mCRPC samples with response to AR-targeted therapy.
First Author: Aishwarya Subramanian
Poster
2023 ASCO Genitourinary Cancers Symposium
Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.
First Author: Alice Bernard-Tessier
Poster
2020 Genitourinary Cancers Symposium
IND candidate EPI-7386 as an N-terminal domain androgen receptor inhibitor in development for the treatment of prostate cancer.
First Author: Ronan Le Moigne